BRPI0510412A - compostos orgánicos - Google Patents

compostos orgánicos

Info

Publication number
BRPI0510412A
BRPI0510412A BRPI0510412-2A BRPI0510412A BRPI0510412A BR PI0510412 A BRPI0510412 A BR PI0510412A BR PI0510412 A BRPI0510412 A BR PI0510412A BR PI0510412 A BRPI0510412 A BR PI0510412A
Authority
BR
Brazil
Prior art keywords
organic compounds
compounds
medicaments
formula
preparation
Prior art date
Application number
BRPI0510412-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Peter Herold
Robert Mah
Vincenzo Tschinke
Christoph Schumacher
Michael Quirmbach
Dirk Behnke
Original Assignee
Speedel Experimenta Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Speedel Experimenta Ag filed Critical Speedel Experimenta Ag
Publication of BRPI0510412A publication Critical patent/BRPI0510412A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0510412-2A 2004-05-28 2005-05-27 compostos orgánicos BRPI0510412A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH9162004 2004-05-28
CH11572004 2004-07-09
PCT/EP2005/052418 WO2005118541A2 (en) 2004-05-28 2005-05-27 Heterocyclic compounds and their use as aldosterone synthase inhibitors

Publications (1)

Publication Number Publication Date
BRPI0510412A true BRPI0510412A (pt) 2007-10-23

Family

ID=34993240

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510412-2A BRPI0510412A (pt) 2004-05-28 2005-05-27 compostos orgánicos

Country Status (11)

Country Link
US (1) US20080076794A1 (enExample)
EP (1) EP1748986B1 (enExample)
JP (1) JP2008500999A (enExample)
AR (1) AR050251A1 (enExample)
AT (1) ATE490241T1 (enExample)
BR (1) BRPI0510412A (enExample)
CA (1) CA2568164A1 (enExample)
DE (1) DE602005025110D1 (enExample)
IL (1) IL179409A0 (enExample)
TW (1) TW200608978A (enExample)
WO (1) WO2005118541A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0511621A (pt) * 2004-05-28 2008-01-02 Speedel Experimenta Ag compostos orgánicos
TW200716105A (en) * 2005-05-31 2007-05-01 Speedel Experimenta Ag Imidazole compounds
TW200804378A (en) * 2005-12-09 2008-01-16 Speedel Experimenta Ag Organic compounds
EP1842543A1 (en) 2006-04-05 2007-10-10 Speedel Pharma AG Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist
TW200808813A (en) * 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
TW200808812A (en) * 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
EP1886695A1 (en) * 2006-06-27 2008-02-13 Speedel Experimenta AG Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist
RS53664B1 (sr) 2009-05-28 2015-04-30 Novartis Ag Supstituisani derivati aminopropionske kiseline kao inhibitori neprilizina
JP5466759B2 (ja) 2009-05-28 2014-04-09 ノバルティス アーゲー ネプリライシン阻害剤としての置換アミノ酪酸誘導体
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
SG10201605304VA (en) 2011-07-08 2016-08-30 Novartis Ag Method of treating atherosclerosis in high triglyceride subjects
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
SI2956464T1 (en) 2013-02-14 2018-08-31 Novartis Ag Substituted bisphenyl butanoic phosphonic acid derivatives as NEP inhibitors (neutral endopeptidases)
CN105705167A (zh) 2013-07-25 2016-06-22 诺华股份有限公司 合成的apelin多肽的生物缀合物
EP3024845A1 (en) 2013-07-25 2016-06-01 Novartis AG Cyclic polypeptides for the treatment of heart failure
CU20170093A7 (es) 2015-01-23 2017-09-06 Novartis Ag Conjugados de ácidos grasos y apelina sintética con mayor vida media
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
UY38485A (es) 2018-11-27 2020-06-30 Novartis Ag Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación
US20230089867A1 (en) 2018-11-27 2023-03-23 Novartis Ag Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder
CN113166204B (zh) 2018-11-27 2025-01-28 诺华股份有限公司 作为治疗代谢障碍的蛋白质原转换酶枯草杆菌蛋白酶/kexin 9型（PCSK9）抑制剂的环状肽
WO2023084449A1 (en) 2021-11-12 2023-05-19 Novartis Ag Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder
AR127698A1 (es) 2021-11-23 2024-02-21 Novartis Ag Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
US20240391941A1 (en) 2023-05-24 2024-11-28 Novartis Ag Naphthyridinone derivatives for the treatment of a disease or disorder

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859691A (en) * 1987-07-08 1989-08-22 Ciba-Geigy Corporation Certain 1,2-benzisoxazole derivatives
GB8820730D0 (en) * 1988-09-02 1988-10-05 Erba Carlo Spa Substituted 5 6 7 8-tetrahydroimidazo/1.5-a/pyridines & process for their preparation
US5057521A (en) * 1988-10-26 1991-10-15 Ciba-Geigy Corporation Use of bicyclic imidazole compounds for the treatment of hyperaldosteronism
ES2064530T3 (es) * 1989-06-05 1995-02-01 Daiichi Seiyaku Co Compuestos de triazina o triazolo heterociclicos con actividad de antagonista de 2-receptor de serotonina.
JP3170273B2 (ja) * 1989-06-05 2001-05-28 第一製薬株式会社 縮合トリアジン誘導体及びその中間体
CA2026792A1 (en) * 1989-11-01 1991-05-02 Michael N. Greco (6,7-dihydro-5h-pyrrolo[1,2-c]imidazol-5-yl)- and (5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl) substituted 1h-benzotriazole derivatives
JPH07503242A (ja) * 1992-01-27 1995-04-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ アロマターゼ阻害剤としてのピロロイミダゾリルおよびイミダゾピリジニル置換１ｈ−ベンズイミダゾール誘導体
JPH0971586A (ja) * 1995-09-07 1997-03-18 Yamanouchi Pharmaceut Co Ltd 新規な二環性縮合イミダゾール誘導体
CA2422767A1 (en) * 1999-10-22 2001-04-22 Glaxo Group Limited In vivo imaging
US20030083342A1 (en) * 2002-08-27 2003-05-01 Steele Ronald Edward Combination of organic compounds

Also Published As

Publication number Publication date
EP1748986B1 (en) 2010-12-01
CA2568164A1 (en) 2005-12-15
WO2005118541A3 (en) 2006-02-02
AR050251A1 (es) 2006-10-11
WO2005118541A2 (en) 2005-12-15
IL179409A0 (en) 2007-05-15
TW200608978A (en) 2006-03-16
US20080076794A1 (en) 2008-03-27
ATE490241T1 (de) 2010-12-15
EP1748986A2 (en) 2007-02-07
DE602005025110D1 (de) 2011-01-13
JP2008500999A (ja) 2008-01-17

Similar Documents

Publication Publication Date Title
BRPI0510410A (pt) compostos orgánicos
BRPI0510412A (pt) compostos orgánicos
BRPI0510409A (pt) heterociclos bicìclicos contendo nitrogênio como inibidores da aromatase
BRPI0408347B8 (pt) derivados de pirimidina, seu uso, e composição e combinação farmacêuticas
BRPI0717970C1 (pt) composto inibidor de 11betahsd1, composição farmacêutica, e, uso do composto
BRPI0506843A (pt) composto, composição farmacêutica, processo para a preparação de um composto, e, uso de um composto
BRPI0514125A (pt) piridinas condensadas como inibidores de cinase
BRPI0712631B8 (pt) compostos, processos para a preparação de um composto, composição farmacêutica, uso de um composto e combinações
BRPI0518758A2 (pt) compostos de acetamida como fungicidas
BRPI0512938A (pt) derivados da quinazolinediona como inibidores parp
BRPI0510273A (pt) derivados de tetraazabenzo[e]azuleno e análogos destes
BRPI0512060A (pt) compostos orgánicos
BRPI0514841A (pt) inibidores de piridila da sinalização de hedgehog, processo de preparação dos mesmos e composição compreendendo os referidos inibidores
BRPI0709633B8 (pt) derivados de piridina e pirimidina como antagonistas de mglur2, composição farmacêutica e uso dos mesmos
BRPI0512797A (pt) derivados de quinazolinona como inibidores de parp
BR0314379A (pt) Quinazolinonas espirocondensadas e a sua utilização como inibidores de fosfodiesterase
TW200613274A (en) Organic compounds
BRPI0712889A8 (pt) composto, processo para a preparação de um composto, composto intermediário, e, composição farmacêutica.
BRPI0900983B8 (pt) composto de diometina, processo para a síntese do mesmo, composição farmacêutica e seu uso
BRPI0514731A (pt) derivados de pirimidina
BRPI0414948A (pt) derivados de pirazolo-e-imidazo pirimidina
TW200611897A (en) Organic compounds
BR0307461A (pt) Derivados de quinazolinona e seu uso como agonistas de cb
BRPI0508969A (pt) compostos orgánicos
BR112012030534A2 (pt) moduladores de receptores 5-ht e métodos de uso dos mesmos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.